Part 3.7 / M18
3. DEEL 3: GEHARMONISEERDE INDELING EN ETIKETTERING
|
Catalogusnummer |
►M18 Chemische naam ◄ |
EG-nr. |
CAS-nr. |
Indeling |
Etikettering |
►M18 Specifieke concentratiegrenzen, M-factoren en ATE's (*1) ◄ |
Opmerkingen |
|||
|
Gevarenklasse en -categorie |
Gevarenaanduiding |
Pictogram, signaalwoord |
Gevarenaanduiding |
Aanvullende gevarenaanduiding |
||||||
|
006-044-00-7 |
isoproturon (ISO); 3-(4-isopropylfenyl)-1,1-dimethylureum |
251-835-4 |
Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H373 (bloed) H400 H410 |
GHS08 GHS09 Wng |
H351 H373 (bloed) H410 |
|
M = 10 M = 10 |
|
|
|
015-101-00-5 |
fosmet (ISO); S-[(1,3-dioxo-1,3-dihydro-2H-isoïndool-2-yl)methyl]-O,O-dimethyldithiofosfaat; O,O-dimethyl-S-ftaalimidomethyldithiofosfaat |
211-987-4 |
Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H332 H301 H370 (zenuwstelsel) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H361f H332 H301 H370 (zenuwstelsel) H410 |
|
M = 100 M = 100 |
|
|
|
016-096-00-2 |
thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazine-2-ylcarbamoylsulfamoyl)thiofeen-2-carboxylaat |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 100 M = 100 |
|
|
|
017-011-00-1 |
natriumhypochloriet, oplossing … % actief Cl |
231-668-3 |
Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H318 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
EUH031 |
M = 10 M = 1 EUH031: C ≥ 5 % |
B |
|
|
025-002-00-9 |
kaliumpermanganaat |
231-760-3 |
Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H272 H361d H302 H400 H410 |
GHS03 GHS08 GHS07 GHS09 Dgr |
H272 H361d H302 H410 |
|
|
|
|
|
603-180-00-4 |
colecalciferol; cholecalciferol; vitamine D3 |
200-673-2 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 |
H330 H310 H300 H372 |
GHS06 GHS08 Dgr |
H330 H310 H300 H372 |
|
inademing: ATE = 0,05 mg/L (stofdeeltjes of nevels) dermaal: ATE = 50 mg/kg lg oraal: ATE = 35 mg/kg lg STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 % |
|
|
|
604-014-00-3 |
chloorcresol; 4-chloor-m-cresol; 4-chloor-3-methylfenol |
200-431-6 |
Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3 |
H302 H314 H318 H335 H317 H400 H412 |
GHS07 GHS05 GHS09 Dgr |
H302 H314 H335 H317 H410 |
|
M = 1 |
|
|
|
604-016-00-4 |
1,2-dihydroxybenzeen; pyrocatechol |
204-427-5 |
Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 |
H350 H341 H311 H301 H315 H319 |
GHS08 GHS06 Dgr |
H350 H341 H311 H301 H315 H319 |
|
oraal: ATE = 300 mg/kg lg dermaal: ATE = 600 mg/kg lg |
|
|
|
604-090-00-8 |
4-tert-butylfenol |
202-679-0 |
Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1 |
H361f H315 H318 H410 |
GHS08 GHS05 GHS09 Dgr |
H361f H315 H318 H410 |
|
M = 1 |
|
|
|
604-094-00-X |
iso-eugenol; [1] (E)-2-methoxy-4-(prop-1-enyl)fenol; [2] (Z)-2-methoxy-4-(prop-1-enyl)fenol [3] |
202-590-7 [1] 227-678-2 [2] 227-633-7 [3] |
97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] |
Skin Sens. 1A |
H317 |
GHS07 Wng |
H317 |
|
Skin Sens. 1A; H317: C ≥ 0,01 % |
|
|
605-003-00-6 |
aceetaldehyde; ethanal |
200-836-8 |
Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 |
H224 H350 H341 H335 H319 |
GHS02 GHS08 GHS07 Dgr |
H224 H350 H341 H335 H319 |
|
|
|
|
|
607-096-00-9 |
maleïnezuuranhydride |
203-571-6 |
Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A |
H302 H372 (luchtwegen) (inademing) H314 H318 H334 H317 |
GHS07 GHS08 GHS05 Dgr |
H302 H372 (luchtwegen) (inademing) H314 H334 H317 |
EUH071 |
Skin Sens. 1A; H317: C ≥ 0,001 % |
|
|
|
607-103-00-5 |
barnsteenzuuranhydride |
203-570-0 |
Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H302 H314 H318 H334 H317 |
GHS07 GHS05 GHS08 Dgr |
H302 H314 H334 H317 |
EUH071 |
|
|
|
|
607-113-00-X |
isobutylmethacrylaat |
202-613-0 |
Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B |
H226 H335 H315 H317 |
GHS02 GHS07 Wng |
H226 H335 H315 H317 |
|
|
D |
|
|
607-373-00-4 |
quizalofop-P-tefuryl (ISO); (±)-tetrahydrofurfuryl-(R)-2-[4-(6-chloorchinoxaline-2-yloxy)-fenyloxy]propionaat |
414-200-4 |
Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361fd H302 H373 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361fd H302 H373 H410 |
|
M = 1 M = 1 |
|
|
|
607-724-00-1 |
2,3,5,6-tetrafluor-4-(methoxymethyl)benzyl-(1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-een-1-yl]cyclopropaancarboxylaat; epsilon-metofluthrin |
— |
Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H301 H370 (zenuwstelsel) H373 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H332 H301 H370 (zenuwstelsel) H373 H410 |
|
M = 100 M = 100 |
|
|
|
607-725-00-7 |
isopropyl-(2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-diënoaat; S-methopreen |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 M = 1 |
|
|
|
607-726-00-2 |
pinoxaden (ISO); 8-(2,6-diëthyl-4-methylfenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepine-9-yl-2,2-dimethylpropionaat |
— |
Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 |
H361d H332 H302 H319 H335 H317 H400 H412 |
GHS08 GHS07 GHS09 Wng |
H361d H332 H302 H319 H335 H317 H410 |
|
inademing: ATE = 4,63 mg/L (stofdeeltjes of nevels) oraal: ATE = 500 mg/kg lg M = 1 |
|
|
|
607-727-00-8 |
tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoïndool-2-yl)methyl-2,2-dimethyl-3-(2-methylprop-1-een-1-yl)cyclopropaancarboxylaat |
231-711-6 |
Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H371 (zenuwstelsel) (inademing) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H371 (zenuwstelsel) (inademing) H410 |
|
M = 100 M = 100 |
|
|
|
607-728-00-3 |
(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoïndool-2-yl)methyl-(1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropaancarboxylaat |
214-619-0 |
Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H371 (zenuwstelsel) (inademing) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H371 (zenuwstelsel) (inademing) H410 |
|
M = 100 M = 100 |
|
|
|
607-729-00-9 |
mesosulfuron-methyl (ISO); methyl-2-[(4,6-dimethoxypyrimidine-2-ylcarbamoyl)sulfamoyl]-α-(methaansulfonamido)-p-toluaat; |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 100 M = 100 |
|
|
|
607-730-00-4 |
spirodiclofen (ISO); 3-(2,4-dichloorfenyl)-2-oxo-1-oxaspiro[4.5]dec-3-een-4-yl-2,2-dimethylbutyraat |
— |
Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 |
H350 H361f H373 H317 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H361f H373 H317 H410 |
|
M = 10 |
|
|
|
607-731-00-X |
natrium-methyl-[(4-aminofenyl)sulfonyl]carbamaat; natrium-methyl-(EZ)-sulfanilylcarbonimidaat; asulam-natrium |
218-953-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 1 M = 1 |
|
|
|
607-732-00-5 |
salicylzuur |
200-712-3 |
Repr. 2 Acute Tox. 4 Eye Dam. 1 |
H361d H302 H318 |
GHS08 GHS07 GHS05 Dgr |
H361d H302 H318 |
|
|
|
|
|
608-068-00-9 |
flutianil (ISO); (2Z)-{[2-fluor-5-(trifluormethyl)fenyl]thio}[3-(2-methoxyfenyl)-1,3-thiazolidine-2-ylideen]acetonitril |
— |
Aquatic Chronic 1 |
H410 |
GHS09 Wng |
H410 |
|
M = 100 |
|
|
|
612-293-00-8 |
reactiemassa van 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine en 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine |
447-920-2 |
— |
Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 |
H361f H302 H314 H318 |
GHS08 GHS07 GHS05 Dgr |
H361f H302 H314 |
EUH071 |
|
|
|
613-167-00-5 |
reactiemassa (3:1) van 5-chloor-2-methyl-2H-isothiazool-3-on en 2-methyl-2H-isothiazool-3-on |
— |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H301 H314 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H310 H301 H314 H317 H410 |
EUH071 |
Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 |
B |
|
|
613-205-00-0 |
propiconazool (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichloorfenyl)-4-propyl-1,3-dioxolaan-2-yl]methyl}-1H-1,2,4-triazool |
262-104-4 |
Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360D H302 H317 H410 |
|
M = 1 M = 1 |
|
|
|
613-326-00-9 |
2-methylisothiazool-3(2H)-on |
220-239-6 |
Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H311 H301 H314 H318 H317 H400 H410 |
GHS05 GHS06 GHS09 Dgr |
H330 H311 H301 H314 H317 H410 |
EUH071 |
Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1 |
|
|
|
613-327-00-4 |
pyroxsulam (ISO); N-(5,7-dimethoxy[1,2,4]triazool[1,5-a]pyrimidine-2-yl)-2-methoxy-4-(trifluormethyl)pyridine-3-sulfonamide |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 100 M = 100 |
|
|
|
613-328-00-X |
1-vinylimidazool |
214-012-0 |
Repr. 1B |
H360D |
GHS08 Dgr |
H360D |
|
Repr. 1B; H360D: C ≥ 0,03 % |
|
|
|
614-001-00-4 |
nicotine (ISO); 3-[(2S)-1-methylpyrrolidine-2-yl]pyridine |
200-193-3 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 |
H330 H310 H300 H411 |
GHS06 GHS09 Dgr |
H330 H310 H300 H411 |
|
inademing: ATE = 0,19 mg/L (stofdeeltjes of nevels) dermaal: ATE = 70 mg/kg lg oraal: ATE = 5 mg/kg lg |
|
|
|
616-224-00-2 |
amisulbrom (ISO); 3-3-(broom-6-fluor-2-methylindool-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazool-1-sulfonamide |
— |
Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H319 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H319 H410 |
|
M = 10 M = 10 |
|
|